Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CRHBP | P24387 | 2/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897129 | 0.81 | HRH4 (0.55) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL7676555 | 0.79 | CYP1A2 (0.50) | KMT2ACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL5896965 | 0.77 | HRH3 (0.43) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL5897044 | 0.76 | HRH4 (0.50) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL27892245 | 0.74 | KMT2A (0.46) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL970205 | 0.73 | KMT2A (0.67) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL1515189 | 0.73 | HTR3E (0.66) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL9885000 | 0.73 | KMT2A (0.53) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| SCHEMBL12110419 | 0.71 | KMT2A (0.65) | KMT2ACRHBPCRHR2NPSR1HRH4 | |
| Ammonia Solution, Strong SCHEMBL28507641 | 0.71 | HTR3E (0.64) | KMT2ACRHBPCRHR2NPSR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | KMT2A 3984/4885CRHBP 4777/4885CRHR2 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.